Nucleoside transporters: molecular biology and implications for therapeutic development.

The uptake of nucleosides (or nucleobases) is essential for nucleic acid synthesis in many human cell types and in parasitic organisms that cannot synthesize nucleotides de novo. The transporters responsible are also the route of entry for many cytotoxic nucleoside analogues used in cancer and viral chemotherapy. Moreover, by regulating adenosine concentrations in the vicinity of its cell-surface receptors, nucleoside transporters profoundly affect neurotransmission, vascular tone and other processes. The recent molecular characterization of two families of human nucleoside transporters has provided new insights into the mechanisms of natural nucleoside and drug uptake and into future developments of improved therapies.

[1]  S. Yao,et al.  Chimeric Constructs between Human and Rat Equilibrative Nucleoside Transporters (hENT1 and rENT1) Reveal hENT1 Structural Domains Interacting with Coronary Vasoactive Drugs* , 1998, The Journal of Biological Chemistry.

[2]  G. Allen Genetics, eugenics and the medicalization of social behavior: lessons from the past. , 1999, Endeavour.

[3]  J. Mackey,et al.  Nucleoside transport and its significance for anticancer drug resistance. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  S. Yao,et al.  Cloning of a human nucleoside transporter implicated in the Cellular uptake of adenosine and chemotherapeutic drugs , 1997, Nature Medicine.

[5]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[6]  J. Lloberas,et al.  Na+-dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells. , 1998, The Biochemical journal.

[7]  N. Curtin,et al.  Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Moore Utilization of mouse models in the discovery of human disease genes. , 1999, Drug discovery today.

[9]  C. Cass,et al.  Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity for pyrimidine nucleosides (cNT1rat) by transient expression in cultured mammalian cells. , 1996, The Biochemical journal.

[10]  H. D. de Koning,et al.  Characterization of a Nucleoside/Proton Symporter in ProcyclicTrypanosoma brucei brucei * , 1998, The Journal of Biological Chemistry.

[11]  J. Schrader,et al.  Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. , 1997, Circulation research.

[12]  J. Koeller,et al.  Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. , 1988, Cancer research.

[13]  J. Crabbe,et al.  Identifying genes for alcohol and drug sensitivity: recent progress and future directions , 1999, Trends in Neurosciences.

[14]  Farina,et al.  Selective inhibitors of the osteoclast vacuolar proton ATPase as novel bone antiresorptive agents. , 1999, Drug discovery today.

[15]  K. Mullane,et al.  Role of adenosine in the heart and circulation. , 1996, Cardiovascular research.

[16]  C. Cass,et al.  Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain. , 1996, Brain research. Molecular brain research.

[17]  J. Mackey,et al.  Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. , 1998, Molecular membrane biology.

[18]  K. Woodward,et al.  Proteolipid protein gene: Pelizaeus-Merzbacher disease in humans and neurodegeneration in mice. , 1999, Trends in genetics : TIG.

[19]  J. Pearson,et al.  Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter. , 1996, The Biochemical journal.

[20]  L. Dagnino,et al.  Sodium-dependent and equilibrative nucleoside transport systems in L1210 mouse leukemia cells: effect of inhibitors of equilibrative systems on the content and retention of nucleosides. , 1990, Cancer research.

[21]  J. Wiley,et al.  Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia. , 1987, Australian and New Zealand journal of medicine.

[22]  A. W. Senft,et al.  Purine metabolism in Schistosoma mansoni. , 1972, International journal for parasitology.

[23]  S. Beverley,et al.  Cloning of Leishmania nucleoside transporter genes by rescue of a transport-deficient mutant. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Faaland,et al.  Molecular characterization of two novel transporters from human and mouse kidney and from LLC-PK1 cells reveals a novel conserved family that is homologous to bacterial and Aspergillus nucleobase transporters. , 1998, Biochimica et biophysica acta.

[25]  J. Mackey,et al.  Nucleoside transporters of mammalian cells. , 1999, Pharmaceutical biotechnology.

[26]  M. P. Gallagher,et al.  Cloning of the nupC gene of Escherichia coli encoding a nucleoside transport system, and identification of an adjacent Insertion element, IS 186 , 1994, Molecular microbiology.

[27]  K. Giacomini,et al.  Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. , 1997, The American journal of physiology.

[28]  A. Fairlamb,et al.  Arsenical-resistant trypanosomes lack an unusual adenosine transporter , 1993, Nature.

[29]  A. Fairlamb,et al.  The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. , 1999, Parasitology today.

[30]  J. Wiley,et al.  Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. , 1982, The Journal of clinical investigation.

[31]  S. Yao,et al.  Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. , 1997, The Biochemical journal.

[32]  I. Arias,et al.  Primary Structure and Functional Expression of a cDNA Encoding the Bile Canalicular, Purine-specific Na+-Nucleoside Cotransporter (*) , 1995, The Journal of Biological Chemistry.

[33]  D. Klatzmann,et al.  Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation? , 1999, Immunology today.

[34]  S. Yao,et al.  Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes. , 1996, Molecular pharmacology.

[35]  S. Yao,et al.  Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. , 1994, The Journal of biological chemistry.

[36]  K. Mullane,et al.  Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. , 1995, Journal of molecular and cellular cardiology.

[37]  H. van Belle,et al.  Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. , 1987, The American journal of physiology.

[38]  J. Sommadossi,et al.  Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5'-monophosphate for the treatment of schistosomiasis , 1989, Antimicrobial Agents and Chemotherapy.

[39]  K. Giacomini,et al.  Molecular Determinants of Substrate Selectivity in Na+-dependent Nucleoside Transporters* , 1997, The Journal of Biological Chemistry.

[40]  N. Sangster,et al.  Pharmacology of anthelmintic resistance. , 1999, Parasitology today.

[41]  C. R. Crawford,et al.  Cloning of the Human Equilibrative, Nitrobenzylmercaptopurine Riboside (NBMPR)-insensitive Nucleoside Transporter ei by Functional Expression in a Transport-deficient Cell Line* , 1998, The Journal of Biological Chemistry.

[42]  D. Griffith,et al.  Nucleoside and nucleobase transport systems of mammalian cells. , 1996, Biochimica et biophysica acta.

[43]  A W Murray,et al.  The biological significance of purine salvage. , 1971, Annual Review of Biochemistry.

[44]  N. Curtin,et al.  Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. , 1997, British Journal of Cancer.

[45]  R. Mentzer,et al.  Myocardial protection: The adenosine story , 1996 .

[46]  J. Shryock,et al.  Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. , 1997, The American journal of cardiology.

[47]  T. Greten,et al.  MHC-based diagnostics and therapeutics - clinical applications for disease-linked genes. , 1999, Immunology today.

[48]  A. deFazio,et al.  Regional variation in human extracellular purine levels. , 1983, The Journal of laboratory and clinical medicine.

[49]  E. Krug,et al.  Purine and Pyrimidine Metabolism , 1995 .

[50]  S. Yao,et al.  Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). , 1997, The American journal of physiology.